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HLA class I–restricted CD8+ CTL responses 
have  been  associated  with  viral  containment 
during acute infection and are thought to con-
tribute to the establishment of viral setpoint in 
the chronic stages of infection (Borrow et al., 
1994; Koup et al., 1994; Jin et al., 1999; Schmitz 
et al., 1999; Brander et al., 2006; Northfield   
et al., 2007; Streeck et al., 2009). Aside from 
CTL epitopes located in proteins encoded by 
HIV open reading frames (ORFs), recent data 
point toward the existence of epitopes in pro-
tein sequences encoded by frameshifted HIV 
(Cardinaud et al., 2004) and SIV nucleotide   
sequences (Maness et al., 2007). Such alterna-
tive reading frame (ARF)–encoded epitopes 
have been reported in a variety of human dis-
eases, including influenza infection, malignan-
cies, and autoimmunity (Bullock and Eisenlohr, 
1996; Wang et al., 1996; Bullock et al., 1997; 
Rimoldi et al., 2000; Probst-Kepper et al., 2001; 
Saeterdal et al., 2001; Saulquin et al., 2002), but 
they may occur at particularly high frequency 
in  HIV  and  other  retroviral  pathogens  that 
show frequent nucleotide deletions or inser-
tions in their genome. Early studies in mouse 
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CD8+ cytotoxic T lymphocyte (CTL)–mediated immune responses to HIV contribute to viral 
control in vivo. Epitopes encoded by alternative reading frame (ARF) peptides may be 
targeted by CTLs as well, but their frequency and in vivo relevance are unknown. Using host 
genetic (human leukocyte antigen [HLA]) and plasma viral sequence information from 765 
HIV-infected subjects, we identified 64 statistically significant (q < 0.2) associations be-
tween specific HLA alleles and sequence polymorphisms in alternate reading frames of gag, 
pol, and nef that did not affect the regular frame protein sequence. Peptides spanning the 
top 20 HLA-associated imprints were used to test for ex vivo immune responses in 85 HIV-
infected subjects and showed responses to 10 of these ARF peptides. The most frequent 
response recognized an HLA-A*03–restricted +2 frame–encoded epitope containing a 
unique A*03-associated polymorphism at position 6. Epitope-specific CTLs efficiently 
inhibited viral replication in vitro when viruses containing the wild-type sequence but not 
the observed polymorphism were tested. Mutating alternative internal start codons abro-
gated the CTL-mediated inhibition of viral replication. These data indicate that responses 
to ARF-encoded HIV epitopes are induced during natural infection, can contribute to viral 
control in vivo, and drive viral evolution on a population level.
© 2010 Berger et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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AIDS and the recent reports in HIV and SIV infections 
suggest that immune responses mounted against such frame-
shifted epitopes could potentially contribute to viral control 
in vivo (Mayrand et al., 1998; Ho and Green, 2006). Indeed, 
CTLs targeting an HLA-B*07–restricted ARF epitope, first 
identified in HLA-B*07 transgenic mice, were able to recog-
nize HIV-infected cells and kill peptide-pulsed antigen-pre-
senting cells (Cardinaud et al., 2004). Moreover, ARF epitope 
–specific CTLs inhibited SIV replication in autologous in-
fected cells in vitro and appeared to select for viral escape 
variants that abrogated the epitope binding to Mamu-B*17 
in vivo (Yant et al., 2006; Maness et al., 2007).
The analysis of immune escape mutations in HIV-infected 
individuals expressing specific HLA class I alleles has allowed 
for the identification of HLA class I allele–specific “foot-
prints,” which reflect the accumulation of particular HIV se-
quence polymorphisms in individuals carrying or lacking a 
specific HLA class I allele (Moore et al., 2002; Leslie et al., 
2005;  Bhattacharya  et  al.,  2007;  Rousseau  et  al.,  2008; 
Brumme et al., 2009). The presence of such HLA footprints 
is thought to represent direct evidence for in vivo immune 
selection pressure on the virus by the host cellular immune 
response. Importantly, these footprints have also facilitated   
the  identification  of  novel  CTL  epitopes  in  HIV  coding   
sequences, although the presentation of individual epitopes 
on  several  HLA  alleles  may  complicate  the  interpretation 
(Bhattacharya et al., 2007; Frahm et al., 2007).
Little is known about the potential in vivo relevance of 
ARF epitopes and how responses against such targets could 
affect viral evolution. To address this, we assessed the pres-
ence and frequency of HLA-associated viral polymorphisms 
that were statistically significant in one or more ARFs but not 
in the primary ORF (e.g., synonymous changes) in a large 
cohort of 765 untreated, chronically HIV-infected individuals 
(Brumme et al., 2007, 2008). Our data indicate that cellular 
immune responses to ARF-encoded sequences are not infre-
quent in HIV-infected individuals and that these responses 
can inhibit viral replication in vitro. Their in vivo relevance 
is further reflected by the identification of HLA class I allele–
specific associations with particular viral polymorphisms that 
did not affect the amino acid sequence in the original reading 
frame yet represent effective escape from ARF epitope–specific 
CTL populations.
RESULTS
Population-level HLA-associated viral polymorphisms  
in ARF sequences indicate CTL-mediated immune pressure
To identify ARF-directed T cell responses and to assess pop-
ulation-wide immune selection pressure mediated by these 
responses, HIV gag, pol, and nef sequences from a cohort of 
765 individuals were analyzed for HLA allele–associated se-
quence polymorphisms in ARFs (Brumme et al., 2007, 2008). 
All nucleotide sequences were initially translated in the puta-
tive +1 and +2 reading frames and analyzed for HLA class I 
allele–associated viral polymorphisms, as previously described 
(Carlson et al., 2008). A correction for multiple comparisons 
using a q-value approach (Storey and Tibshirani, 2003) was 
applied, and associations with a false discovery rate of 20% or 
lower (q < 0.2) were included. A total of 64 HLA-associated 
viral polymorphisms unique to the ARF were identified in 
gag (29 associations), pol (27 associations), and nef (8 associa-
tions). Of these, 12, 18, and 7 were derived from +1 shifted 
reading frames and 17, 9, and 1 were derived from +2 shifted 
sequences, respectively (Table I). It is important to note that 
the HLA-associated polymorphisms listed in Table I were 
not reflected in the coding sequence of the HIV protein, 
and these associations are unique to the +1 and/or +2 ARF 
only. Indeed, our method also identified HLA-associated 
polymorphisms in the coding sequence, which resulted in 
(statistically significant) nonsynonymous substitutions in the 
+1 and +2 frames, but these were excluded from further 
analysis  as  we  conservatively  assumed  that  these  imprints 
were driven by immune responses to the known HIV pro-
teins.  Furthermore,  all  HLA-associated  polymorphisms  in 
ARF that had an HLA association with any HLA allele within 
±2  amino  acids  in  the  corresponding  primary  coding  se-
quence were also excluded from analysis (for a complete list 
of imprints see Table S1).
According to a recent publication that introduces a con-
sistent nomenclature of HLA-associated viral polymorphisms 
(Brumme et al., 2009), the associations identified in this study 
are referred to as adapted and nonadapted forms. Adapted 
forms (also commonly called escape variants) are amino acids 
significantly enriched in the presence of the HLA allele in 
question (and vice versa). Nonadapted forms (also commonly 
called wild-type or susceptible forms) are amino acids signifi-
cantly depleted in the presence of the HLA allele in question 
(and vice versa).
Peptides spanning regions of ARF sequence polymorphisms 
are targeted by HIV-infected individuals
To investigate if the observed HLA-associated polymorphisms   
could in fact be the result of viral adaptation to CTL-mediated 
immune pressure on alternative-frame HIV peptides, in vitro 
T cell responses to ARF peptides spanning the region of   
the associations were assessed. Peptides were synthesized to   
either contain the identified imprint in the center of two 
overlapping peptide (OLP) sequences (between 13 and 20 
amino acids in length, and overlapping by 9–10 amino acids) 
or as short (9–12 amino acids long) predicted CTL epitopes 
using  a  recently  developed  epitope  prediction  algorithm 
(Heckerman et al., 2007), and were then tested by ex vivo 
IFN- ELISPOT assay using PBMCs from untreated, chroni-
cally HIV-infected individuals. Peptides included 9 sequences 
from the +1 ORF and 12 from the +2 ORF, covering 10, 8, 
and 2 regions of imprints in gag, pol, and nef, respectively 
(Table II). Responses were observed in 21 out of 85 HIV-
infected individuals and 0 out of 32 HIV-negative individuals 
tested (P = 0.001 using Fisher’s exact test), indicating that re-
sponses are HIV specific (Fig. 1 A). Of note, there was no sta-
tistical difference in HLA class I allele representation between 
the HIV-infected and -uninfected individuals, indicating that JEM VOL. 207, January 18, 2010 
Article
63
allele  for  which  an  imprint  was  present  in  that  region.   
Although these situations were less frequent (19 out of the 
27 responses detected were observed in subjects expressing 
either the imprint allele [n = 8] or at least an HLA super-
type–matched allele [n = 11]), 8 responses were unexpected 
based on the HLA type of the tested individual. The recently 
described extensive HLA promiscuity even among optimally 
defined CTL epitopes and the fact that the in vitro testing 
was based on longer peptide sequences that may contain 
multiple epitopes presented by different HLA alleles likely 
explain the detection of these responses in the absence of 
the imprint HLA alleles (Goulder et al., 2000; Frahm et al., 
2002; Frahm et al., 2007). Among the reactive peptides, three 
regions (four peptides) were targeted by >1 out of the 21 re-
active individuals (Fig. 1 C). In particular, the GQQRST-
LERTSKASLER (GR17 peptide) sequence was recognized 
by 10 individuals of whom all but 1 expressed either HLA-
A*03 or an HLA-A*03 supertype allele (Table III; Sidney   
et al., 2008). The median magnitude of the response was 185 
SFCs/106 PBMCs (range: 70–640 SFCs/106 PBMCs). This 
peptide spanned the site of the strongest imprint identified 
in this study (P = 1.78 × 108; q = 0.000048), which was   
indeed associated with an adapted polymorphism in the   
the HIV-negative group was a suitable control population 
(Tables S2 and S3).
Among the 21 subjects with responses, 27 peptide-specific 
activities were seen with a median magnitude of 140 spot-
forming cells (SFCs)/106 PBMCs (range: 50–820 SFCs/106 
PBMCs; Fig. 1 B). Responses in seven individuals were re-
confirmed by intracellular cytokine staining using flow cy-
tometry and were in all cases mediated by CD8 T cells (not 
depicted). The frequency of individuals with detectable re-
sponses (24.7%) is comparable to that seen to first-frame 
responses to HIV protease, Vpu, Rev, Tat, and Vif (11–40% 
of responders, based on protein-specific peptide sets ranging 
from 9 to 24 OLPs). These proteins are consistently among 
the less frequently targeted HIV proteins (Frahm et al., 2004; 
Zuñiga et al., 2006) that elicit responses of comparable mag-
nitude (all P > 0.05; Zuñiga et al., 2006). Thus, although of 
lower magnitude and frequency than responses to dominant 
targets such as HIV Gag, RT, and Nef, responses to ARF 
were well above stringent assay backgrounds, also reflected 
by the fact that no spurious responses were seen in HIV-un-
infected subjects (Fig. 1 A). Interestingly, the responses to the 
tested predicted ARF epitopes and longer ARF peptides did 
not occur exclusively in the individuals expressing the HLA 
Figure 1.  Magnitude and breadth of CTL responses to frameshift-derived peptides. (A–C) 85 HIV-infected individuals and 32 HIV-negative con-
trols were tested for CTL responses in ex vivo IFN- ELISPOT using fresh PBMCs. 21 out of 85 patients displayed a CTL response to at least one of the pep-
tides tested. Peptides were exclusively recognized in HIV-infected individuals. (A) The number of peptides targeted by each individual tested is shown (A). 
Magnitude of responses in the IFN- ELISPOT is expressed as SFCs/106 PBMCs. The horizontal bar represents the median magnitude (B). The frequency and 
sequence of the responses to individual peptides are shown. All peptides tested and the respective number of patients mounting a CTL response are indi-
cated. The 17mer GQQRSTLERTSKASLER (GR17) was recognized by 10 out of the 85 individuals tested (C).64 Immune selection pressure to frameshift epitopes | Berger et al.
Table I.  HLA-associated viral polymorphisms in the +1 and +2 ARFs
RF Protein Association HLA Pos HXB2 aa p-value q-value Dist
+1 Gag Adapted C05 12 T 4.76 × 104 1.91 × 101 14
+1 Gag Nonadapted A03 45 Q 1.47 × 104 1.02 × 101 13
+1 Gag Adapted A29 86 F 1.07 × 104 7.94 × 102 5
+1 Gag Adapted B40 99 R 3.42 × 104 1.73 × 101 4
+1 Gag Adapted B08 132 T 3.84 × 104 1.73 × 101 5
+1 Gag Nonadapted A23 138 S 2.04 × 104 1.23 × 101 8
+1 Gag Adapted C06 168 S 8.89 × 105 6.79 × 102 20
+1 Gag Adapted B57 253 T 4.41 × 104 1.85 × 101 11
+1 Gag Nonadapted B57 253 I 4.43 × 104 1.85 × 101 11
+1 Gag Adapted B48 321 Y 3.08 × 104 1.64 × 101 9
+1 Gag Nonadapted B48 321 C 3.08 × 104 1.64 × 101 9
+1 Gag Nonadapted B52 499 H 4.07 × 104 1.76 × 101 17
+1 pol (pro) Adapted A01 73 A 4.26 × 106 3.55 × 103 10
+1 pol (RT) Adapted B07 25 P 2.87 × 104 1.18 × 101 10
+1 pol (RT) Adapted A01 53 K 2.17 × 104 9.2 × 102 18
+1 pol (RT) Adapted B46 151 K 1.49 × 104 7.66 × 102 7
+1 pol (RT) Nonadapted B46 151 R 1.53 × 104 7.66 × 102 7
+1 pol (RT) Nonadapted B40 258 R 5.1 × 104 1.74 × 101 13
+1 pol (RT) Adapted B40 258 K 5.1 × 104 1.74 × 101 13
+1 pol (RT) Adapted B58 271 M 8.2 × 105 4.93 × 102 6
+1 pol (RT) Adapted B14 305 R 5.63 × 104 1.84 × 101 8
+1 pol (RT) Nonadapted B14 305 K 5.63 × 104 1.84 × 101 8
+1 pol (RT) Adapted C06 326 * 5.75 × 104 1.86 × 101 3
+1 pol (RT) Nonadapted B27 356 E 4.39 × 104 1.58 × 101 11
+1 pol (int) Adapted B44 153 L 1.15 × 104 6.49 × 102 3
+1 pol (int) Adapted A03 240 N 2.4 × 104 101 6
+1 pol (int) Nonadapted A03 240 S 3.22 × 104 1.26 × 101 6
+1 pol (int) Nonadapted A03 241 F 1.78 × 108 3.55 × 105 7
+1 pol (int) Adapted A03 241 S 3.06 × 105 2.03 × 102 7
+1 pol (int) Nonadapted A23 241 F 3.56 × 104 1.33 × 101 7
+1 Nef Nonadapted B13 24 S 4.34 × 104 1.02 × 101 3
+1 Nef Adapted C05 28 M 6.29 × 104 1.3 × 101 4
+1 Nef Adapted A02 28 P 9.83 × 104 1.74 × 101 4
+1 Nef Nonadapted B18 58 * 4.28 × 104 1.02 × 101 4
+1 Nef Nonadapted B44 146 Y 8.49 × 104 1.6 × 101 3
+1 Nef Adapted C15 158 K 3.01 × 104 7.77 × 102 3
+1 Nef Adapted A24 177 K 1.41 × 104 3.98 × 102 3
+2 Gag Adapted C05 12 L 4.76 × 104 1.8 × 101 14
+2 Gag Nonadapted A03 45 S 5.19 × 105 4.08 × 102 13
+2 Gag Nonadapted C06 53 S 5.29 × 105 4.08 × 102 5
+2 Gag Adapted B40 99 G 3.42 × 104 1.51 × 101 4
+2 Gag Adapted A68 123 R 9.03 × 106 1.16 × 102 4
+2 Gag Nonadapted A23 138 P 1.82 × 104 1.04 × 101 8
+2 Gag Adapted C06 168 H 8.89 × 105 6.22 × 102 20
+2 Gag Nonadapted B49 183 F 1.47 × 104 9.18 × 102 28
+2 Gag Adapted B57 253 P 4.61 × 104 1.8 × 101 11
+2 Gag Nonadapted B57 253 S 4.61 × 104 1.8 × 101 11
+2 Gag Adapted C02 272 S 2.31 × 104 1.15 × 101 4
+2 Gag Adapted B48 298 S 5.09 × 104 1.9 × 101 4JEM VOL. 207, January 18, 2010 
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mapping analyses using serial truncations of the GR17 peptide 
were performed (Fig. 2). Binding motif analysis suggested the 
presence of two potentially A*03-restricted epitopes, RTS-
KASLER  (RR9)  and  RSTLERTSK  (RK9;  Fig.  2  B).  As 
shown in Fig. 2 C, the optimal epitope mapped to the 9mer 
sequence RR9. The highly statistically significant HLA-A*03–
associated  ARF  polymorphism  observed  at  the  population 
level mapped to position 6 (underlined) of this epitope (RTS-
KAPLER), suggesting abrogation of TCR recognition as a 
possible mechanism of escape (Shibata et al., 1992; Rudolph 
et  al.,  2006).  Subsequent  HLA  restriction  analysis  using 
partly HLA-matched APCs and RR9-specific T cell lines 
(TCLs) confirmed the restriction of this epitope by HLA-
A*03 (Fig. 2 D). To test whether sequence mutation within 
the RR9 epitope affected CTL recognition, the most com-
mon variants (minimal frequency of 2% in the sequences of the 
765 individuals included in the population-based viral poly-
morphism analysis) were synthesized and tested for their ability 
to elicit T cell activity in RR9 responders (Fig. 3). The three 
tested variants were more common in A*03-positive individu-
als, with two of them producing a significant HLA-associated 
imprint in the initial analysis: RTSKAPLER (A*03-RPR9; 
P = 3.08 × 105; q = 0.0324), RTSKTSLER (A*03-RTR9; 
P = 2.4 × 104; q = 0.153), and RTSKAALER (A*03-RAR9; 
Fig. 3 A). Recognition of these epitope variants was then 
tested in the context of five HLA-A*03–expressing subjects. 
Neither of the subjects tested recognized the A*03-RPR9 or 
the A*03-RTR9. In contrast, two of the HLA-A*03–positive 
and the one HLA-A*03–negative but HLA-A*74–expressing 
individual mounted a detectable response to the A*03-RAR9 
variant. Thus, the amino acid change at position 6 from a serine 
context of HLA-A*03. As indicated in Table II, individuals 
expressing the HLA-A*03 allele were significantly less likely 
to have a serine residue at position 241 in the +2 frameshifted 
integrase sequence compared with HLA-A*03–negative indi-
viduals. The HLA types of all patients with a response to 
GR17 are summarized in Table III. To rule out that the 
observed HLA-A*03 imprint originated from immune pres-
sure on epitopes derived from other reading frames (i.e., the 
original Pol sequence or its +1 ARF), responses in HLA-
A*03–expressing individuals to these regions were assessed. 
Overall, only one HLA-A*03–expressing individual mounted 
a response to the corresponding peptide in ARF +1. In addi-
tion, in listings from the Los Alamos HIV immunology data-
base and in datasets from two clade B–infected cohorts with 
a total of >600 comprehensively tested individuals, no evi-
dence emerges that the corresponding region in the original 
frame (i.e., HIV integrase 241) contains an HLA-A*03 (super-
type)–restricted  epitope  (unpublished  data;  Frahm  et  al., 
2004; Zuñiga et al., 2006). Similarly, available population-
based studies of HLA footprinting provide no evidence of   
an A*03-associated polymorphism in the coding sequence 
(Rousseau et al., 2008; Brumme et al., 2009). Collectively, 
these data suggest that responses to the peptide encoded by 
the +2 ARF, not the integrase coding sequence peptide, 
were driving the observed imprint.
Identification of the optimal HLA-A*03 ARF epitope  
and its associated escape mutation
To further describe the recognized epitope within the GR17 
peptide and to evaluate whether the observed imprint in ARF 
+2 was affecting functional CTL recognition, standard epitope 
Table I.  HLA-associated viral polymorphisms in the +1 and +2 ARFs (Continued)
RF Protein Association HLA Pos HXB2 aa p-value q-value Dist
+2 Gag Adapted B48 321 I 2.32 × 104 1.15 × 101 9
+2 Gag Nonadapted B53 465 G 1.18 × 105 1.29 × 102 12
+2 Gag Adapted B52 499 A 1.95 × 105 1.88 × 102 17
+2 Gag Nonadapted B51 499 T 7.49 × 105 5.41 × 102 17
+2 Gag Nonadapted B52 499 T 9.38 × 105 6.37 × 102 17
+2 pol (pro) Adapted A01 73 H 4.26 × 106 6.86 × 103 10
+2 pol (pro) Nonadapted A01 73 Y 2.61 × 104 1.63 × 101 10
+2 pol (RT) Adapted B07 25 L 2.87 × 104 1.75 × 101 10
+2 pol (RT) Adapted A01 53 K 2.18 × 104 1.49 × 101 18
+2 pol (RT) Adapted B58 271 C 6.64 × 105 6.5 × 102 6
+2 pol (int) Adapted A03 240 T 2.4 × 104 1.53 × 101 6
+2 pol (int) Nonadapted A03 240 A 2.41 × 104 1.53 × 101 6
+2 pol (int) Nonadapted A03 241 S 1.78 × 108 4.84 × 105 7
+2 pol (int) Adapted A03 241 P 3.08 × 105 3.24 × 102 7
+2 Nef Adapted B40 157 * 5.17 × 104 1.25 × 101 4
RF indicates the reading frame relative to the regular coding frame of the respective protein. For associations, adapted forms are amino acids significantly enriched in the 
presence of the HLA allele in question (and vice versa), whereas nonadapted forms (also commonly called wild-type or susceptible forms) are amino acids significantly 
depleted in the presence of the HLA allele in question (and vice versa). HLA indicates the HLA allele for which the association was observed. Pos HXB2 indicates the amino acid 
position in the corresponding HXB2 primary reading frame sequence (Leitner et al., 2005). aa indicates the amino acid for which the HLA-associated polymorphism was 
observed. dist indicates the distance (in amino acids) to the next HLA-associated viral polymorphism (to any HLA allele) in the primary ORF. Asterisks indicate stop codons.66 Immune selection pressure to frameshift epitopes | Berger et al.
was monitored for 7 d of culture. To avoid outgrowth of autol-
ogous virus, CD4+ T cells from an elite controller were used for 
these experiments. An A*03-RR9–specific CD8+ CTL clone 
(Fig. S1) from the same subject was used as an effector cell pop-
ulation and added at different E/T ratios to the infected CD4+ 
cells (Fig. 4). Even at an E/T ratio of 1:10, >80% of the viral 
replication was inhibited at day 7 as compared with infection of 
target cells alone when virus containing the clade B consensus 
sequence was used. In contrast, when using the variant virus 
containing the proline variant (RPR9) or the variant with the 
change at the anchor position that should abrogate binding of 
the epitope to HLA-A*03 (RG9), no relevant inhibition of viral 
replication was observed. Together with the variant recognition 
data derived from experiments with PBMCs (Fig. 3 B), the re-
sults obtained in the viral replication inhibition assay strongly 
suggest that the A*03-RR9 epitope is indeed expressed, pro-
cessed, and presented in HIV-infected cells in sufficient amounts 
to sensitize these cells for CTL-mediated killing.
Alternative start codon usage may reflect a mechanism  
of frameshift epitope expression in infected cells
Different mechanisms leading to the generation of CTL epi-
topes encoded by ARFs have been described in the literature 
(for review see Mayrand and Green, 1998). In particular, the 
presence of upstream alternative splice sites and alternative 
start codons has been suggested to potentially facilitate the 
to an alanine (which did not appear as a common variant in the 
imprint analysis; Table S1) is only variably associated with es-
cape from recognition in the HLA-A3 context (Fig. 3 B).
A*03-RR9–specific CTLs inhibit viral replication in vitro
To demonstrate the expression and presentation of RR9 in in-
fected cells and that the observed polymorphisms were effective 
immune escape variants, we engineered multiple viral constructs 
and assessed them in in vitro inhibition assays. We introduced 
different point mutations on the backbone of a laboratory strain 
(NL4-3), including (a) the clade B consensus variant encoding a 
serine (underlined) at residue 6 (RTSKASLER; RR9), (b) the 
most common, and putative escape form, in A*03-positive in-
dividuals encoding a proline (underlined) at that position (RTS-
KAPLER; RPR9), and (c) a variant containing an amino acid 
change at one of the HLA-binding anchors at position 9 (under-
lined; RTSKASLEG; RG9) to cause the loss of binding capacity 
to the A*0301 allele. We anticipated that the consensus variant 
(RR9) should be recognized by a peptide-specific T cell clone 
derived from an A*03-positive individual, whereas the RPR9 
would  escape  from  recognition.  Similarly,  the  RG9  variant 
should be less well recognized because of reduced HLA binding. 
Importantly, all viral variants were designed to be synonymous 
in the corresponding regular reading frame. To assess viral inhi-
bition, CD4+ T cells were infected with the different viral con-
structs and coincubated with effector cells, and viral replication 
Table II.  HLA imprints and regions tested
RF Protein HLA aa Pos Association p-value q-value Dist Region of imprint
+1 gag B52 H 499 Nonadapted 4.07 × 104 1.76 × 101 17 *LPSDHSLATTPRH*
+1 pol (RT) B07 P 124 Adapted 2.87 × 104 1.18 × 101 10 *SQEWMAQKLNNGH*
+1 pol (RT) A03 F 142 Nonadapted 1.78 × 108 3.55 × 105 7 GTAEIHFGKDQQSFSGKVKGQ
+1 pol (RT) B46 K 149 Adapted 1.49 × 104 7.66 × 102 7 RHQGLDISTMCFHRDGKDHQQYSKVA
+1 pol (RT) B40 R 258 Nonadapted 5.1 × 104 1.74 × 101 13 *CCQKKTAGLSMTYRS*
+1 pol (Int) A03 N 240 Adapted 2.4 × 104 101 6 TGTAEIHFGKDQQSFSGKVKGQ
+1 pol (Int) A03 S 240 Nonadapted 3.22 × 104 1.26 × 101 6 TGTAEIHFGKDQQSFSGKVKGQ
+1 nef A24 K 177 Adapted 1.41 × 104 3.98 × 102 3 *ASMGWMTRRKKC*
+1 nef C15 K 158 Adapted 3.01 × 104 7.77 × 102 3 *KRPMQERTTACYTL*
+2 gag C05 L 12 Nonadapted 4.76 × 104 1.8 × 101 14 GCESVSIKRGRIR*
+2 gag A03 S 45 Nonadapted 5.19 × 105 4.08 × 102 13 TYSMGKQGARTIRS*
+2 gag C06 S 53 Nonadapted 5.29 × 105 4.08 × 102 5 SWPVRNSRRL
+2 gag A68 R 123 Adapted 9.03 × 106 1.16 × 102 4 *HRKQQPGQPKLPYSAE
+2 gag B49 F 183 Nonadapted 1.47 × 104 9.18 × 102 28 HVFSIIRRSHPTRFKHHAKHSGGTSSS
+2 gag B51 T 499 Nonadapted 7.49 × 105 5.41 × 102 17 SFPQITLWQRPLVT*
+2 gag B52 T 499 Nonadapted 9.38 × 105 6.37 × 102 17 SFPQITLWQRPLVT*
+2 gag B53 G 465 Nonadapted 1.18 × 105 1.29 × 102 12 TRANSPTRRELQVWGRDNNSLSEAGAD
+2 pol (Pro) A01 H 73 Nonadapted 4.26 × 106 6.86 × 103 10 *SYRYSISRTYTCQHNWK
+2 pol (RT) B07 L 25 Nonadapted 2.87 × 104 1.75 × 101 10 *TMAIDRRKNKSISRNLY
+2 pol (Int) A03 S 241 Nonadapted 1.78 × 108 4.84 × 105 7 GQQRSTLERTSKASLER*
HLA indicates the HLA allele for which the association was observed. aa indicates the amino acid for which the HLA-associated polymorphism was observed. Pos indicates the 
amino acid position in the corresponding HXB2 primary reading frame sequence (Leitner et al., 2005). For associations, adapted forms are amino acids significantly enriched in 
the presence of the HLA allele in question (and vice versa), whereas nonadapted forms are amino acids significantly depleted in the presence of the HLA allele in question (and 
vice versa). Dist indicates the distance (in amino acids) to the next HLA-associated viral polymorphism (to any HLA allele) in the primary ORF. Region of imprint shows the 
sequences surrounding the imprint (bold). In cases where predicted epitopes were tested, the respective sequence is underlined. *, stop codon.JEM VOL. 207, January 18, 2010 
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expression of ARF sequences (Bullock and Eisenlohr, 1996; 
Mayrand and Green, 1998; Schwab et al., 2004). However, 
none of these mechanisms that could enable or increase the 
expression of such frameshifted sequences has been analyzed 
in HIV/SIV in detail.
Because a known splice acceptor site, SA1, is located right 
upstream of the RR9 epitope (Arrigo et al., 1990), we first 
hypothesized  that  HIV  might  be  making  mistakes  when 
splicing mRNA using this acceptor site. We isolated intracel-
lular HIV mRNA from T cells infected with NL4-3 and am-
plified  putative  splice  variants  by  nested  RT-PCR  using 
forward primers just upstream of Gag and reverse primers just 
downstream of HIV integrase. During PCR amplification a 
short (50-s) elongation time was used to selectively amplify 
splice variants but exclude amplification of genomic RNA. 
PCR  amplicons  were  cloned  into  Escherichia  coli,  and  96 
clones were sequenced and analyzed for evidence of alterna-
tive splice variants. However, all 96 sequences were identical 
and  exhibited  the  expected  splicing  pattern  (unpublished 
data), suggesting that alternative splicing is not the major 
mechanism of production of the RR9 ARF peptide.
We then investigated if initiation of translation at a start 
codon  in  the  ARF  upstream  of  the  epitope  could  be  a 
mechanism whereby the ARF peptide is produced in vivo. 
When the ARF +2 sequence was screened for potential start 
codons  (AUG,  methionine),  the  closest  methionine  was 
found  >100  amino  acids  upstream  of  the  RR9  epitope. 
However, the potential reading frame after this methionine 
was not open, as there were five stop codons between the 
methionine and the RR9 epitope that would abrogate ex-
pression. When searching for alternative (nonmethionine) 
start codons, a leucine residue just 2 amino acid residues up-
stream of the RR9 epitope (Fig. 2 A) was identified and 
found to be extremely conserved in the British Columbia 
cohort  (not  depicted).  Leucine  has  previously  been  de-
scribed to be able to act as an alternative start codon (Schwab 
et al., 2004). To investigate if the RR9 epitope would in-
deed be processed and presented from such a short precursor 
protein and whether this leucine residue in fact acted as an 
alternative start codon, we designed specific viral variants on 
the backbone of an NL4-3 virus containing the RR9 epit-
ope. The leucine residue was changed either to a regular 
start codon (methionine; L→M) or an amino acid that is not 
described as an alternative start codon (valine; L→V). We 
hypothesized that if the leucine indeed acts as an alternative 
start codon for this epitope, the change to a regular start co-
don would increase its expression and hence its inhibition 
by a specific T cell clone. On the other hand, the variant 
with the valine should not be expressed at all and, therefore, 
we expected to see no inhibition of viral replication at all. 
These mutations were again carefully designed to be synony-
mous in the regular reading frame and, therefore, not alter the 
sequence integrity of the original reading frame (Fig. 5 A). 
Using these two viral variants in viral inhibition assays and 
comparing  viral  inhibition  to  the  consensus  variant,  we 
demonstrated that the L→M variant was strongly inhibited 
(Fig. 5 B). Interestingly, this inhibition exceeded the suppres-
sion seen with the virus carrying the leucine (0.9 vs. 3.1 log 
at an E/T ratio of 1:5 at day 7; Fig. 5 D) and, therefore, sug-
gests that the RR9 epitope is more highly expressed in the 
context of a regular start codon. On the other hand, the   
L→V variant was, as expected, not inhibited at all (Fig. 5 C). 
Collectively, these data indicate that expression of the alter-
native leucine is in fact a possible mechanism for RR9 epi-
tope expression in HIV-infected cells.
DISCUSSION
RNA viruses with relatively small genomes, such as HIV, 
human T lymphocyte virus, hepatitis B virus, and hepatitis C 
virus, have found ways to increase the genetic information of 
their genome by encoding essential proteins in different for-
ward or backward reading frames (Jacks et al., 1988; Xu et al., 
2001; Gaudray et al., 2002). Through single or double nucle-
otide deletion or insertions and by the presence of alternative 
start codons, alternative splice sites, or possibly other mecha-
nisms, highly variable pathogens such as RNA-based HIV 
Table III.  HLA types and clinical characteristics of individuals recognizing the GQQRSTLERTSKASLER (GR17) peptide
Patient HLA-A HLA-B HLA-Cw SFCs/106 PBMCs CD4 count VL Clinical course
1 0201/1101 0702/1401 0702/0802 190 393 6,270 Chronic untreated
2 0301/0301 0702/5101 0702/1402 70 147 165,995 Chronic untreated
3 0201/0301 3501/4501 ND /1601 140 371 216,000 Chronic untreated
4 0301/2501 1801/3501 0401/1203 410 286 5,322 Chronic untreated
5 2601/7401 3701/4901 0602/0701 240 109 7,310 Chronic untreated
6 2902/3201 4402/4403 0501/1601 610 582 8,450 Chronic untreated
7 0201/0301 5101/5101 0303/1502 640 791 74 Controller
8 0301/3001 4201/5802 0602/1700 110 344 2,650 Chronic untreated
9 0101/3301 0801/1402 0701/0802 80 540 156,000 Chronic untreated
10 0301/1101 0702/4402 0501/0702 180 553 13,100 Chronic untreated
SFCs/106 PBMCs indicates the magnitude of IFN- ELISPOT responses. CD4 counts are indicated in cells per microliter. VL indicates the viral load in RNA copies per milliliter. 
Clinical course indicates if a patient is chronically HIV infected and untreated or is a spontaneous controller of HIV infection in the absence of any HIV-specific treatment. 
A*03 alleles are bolded to highlight which patients were expressing A*03. ND, not done.68 Immune selection pressure to frameshift epitopes | Berger et al.
Figure 2.  Epitope mapping of A*03-RTSKASLER. HIV sequencing and analysis for HLA-associated polymorphisms revealed that viruses isolated from 
A*03-positive patients show a common S→P change at position 241 in the +2 ARF relative to integrase. The amino acid sequence of this region in all three 
reading frames (RF1–3) and the location relative to the protein-encoding HIV genome (HXB2) are displayed. An A*03-associated imprint was also observed 
in the +1 ARF at the same position (A*03 is associated with an S instead of F at that position). 10 out of 85 individuals tested mounted a response to the 
region in the +2 ARF versus only 1 individual to the +1 ARF region. The shaded sequence indicates the newly identified A*03 epitope (A). The optimal epi-
tope length of the GQQRSTLERTSKASLER (GR17) peptide was determined using sequential peptide truncations. IFN- ELISPOT responses at 100 and 10 µg/ml 
are displayed (B). Functional avidity was determined using serial 10-fold dilutions of the peptides ranging from 100 to 0.0001 µg/ml. The shortest peptide 
with the lowest SD50% was considered the optimal epitope (RTSKASLER; RR9; C). Partly HLA-matched BCLs were used for HLA restriction analyses and 
responses were determined with intracellular cytokine staining. Bars represent the percentage of IFN-–positive CD8+ CTLs (left), and the histogram shows 
IFN- positivity of CD3+ CD8+ gated cells (right). RR9 peptide–loaded BCLs only matched in the A*03 allele (orange and red lines) coincubated with an RR9-
specific effector TCL resulted in an IFN- response comparable to incubation with peptide-loaded autologous BCLs (gray-shaded area). Peptide-loaded BCLs 
matched in the other alleles did not induce IFN- production (gray lines; D). One out of at least three independent experiments is shown.JEM VOL. 207, January 18, 2010 
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peptides is comparable to the frequency at which regulatory 
HIV proteins and the HIV protease protein are being tar-
geted (Frahm et al., 2004; Zuñiga et al., 2006). The magni-
tude of responses is, however, clearly below the level that has 
been  observed  for  regular  HIV  protein–specific  responses 
(Frahm et al., 2004; Zuñiga et al., 2006). As ARF-derived 
epitopes are probably expressed and presented at a lower 
density  than  some  of  the  presumably  more  abundantly   
produced immunodominant Gag-derived epitopes, a lower 
magnitude of the CTL response would not be surprising. In 
addition, responses with median frequencies as reported in 
this study are comparable to infections other than HIV, which 
is known to induce particularly strong responses (Bihl et al.,   
2005). The frequency of responses is also similar to what   
Cardinaud et al. (2004) have reported for a single HLA-B*07–
restricted response in highly active antiretroviral therapy– 
treated individuals. Their HLA-B*07–restricted response was, 
however, not included in our screening, as no HLA-B*07– 
associated imprint in the vicinity of the described ARF epi-
tope was identified, possibly either because of a lack of statistical 
and hepatitis C virus may consistently produce frameshifted 
mRNA sequences, giving rise to alternative viral antigens 
that may be processed and presented by host HLA molecules. 
Indeed, two recent reports, one in HIV and one in SIV, indi-
cate that antigens resulting from ARF translation can serve as 
a source of CTL epitopes against which the host can mount 
a cellular immune response (Cardinaud et al., 2004; Maness 
et al., 2007). The present study expanded on these observa-
tions and addressed whether and how strongly frameshifted 
sequences could be under immune selection pressure on a 
population level. The data also document that common HLA 
allele–driven epitope variants can be effective CTL escape 
mutations and can affect CTL recognition of virally infected 
cells. Finally, a potential mechanism for out-of-frame epitope 
expression, namely the use of an alternative start codon, is 
also supported by our data. Collectively, the data provide for 
the first time evidence that ARF-based epitope sequences 
cannot only induce immune responses comparable in breadth 
to those observed against regulatory HIV proteins, but that 
these HLA-restricted responses specific for an ARF-encoded 
epitope are also able to inhibit viral replication in vivo.   
Furthermore, we demonstrate that HLA-restricted immune 
pressure exerted on ARF peptides is apparently strong enough 
to drive HIV evolution on a population level. Indeed, within 
the studied HLA-A*03–restricted ARF peptide, we document 
and functionally validate an escape mutation occurring at po-
sition 6 of this ARF epitope, which does not affect the cod-
ing sequence of HIV integrase. The results are thus consistent 
with adoptive CTL transfer experiments in mouse retroviral 
infection and provide human experimental data in support of 
recent observations in the SIV model (Ho and Green, 2006; 
Maness et al., 2007).
Since the first report of HLA footprints in HIV sequences 
(Moore et al., 2002), the bioinformatic approaches to identify 
these imprints have been refined and take HIV founder se-
quence effects, HLA linkage disequilibrium, and HIV se-
quence covariation into account (Bhattacharya et al., 2007; 
Carlson et al., 2008; Brumme et al., 2009). Using such a re-
cently developed refined approach, we identified 64 discrete 
HLA-driven imprints across the HIV gag, pol, and nef span-
ning ARF +1 and +2 sequences (Carlson et al., 2008). Their 
distribution across the three proteins (Table I) is shifted as 
more ARF imprints were observed in gag and pol regions 
than in nef, whereas first-frame imprints were more common 
in Nef (Brumme et al., 2009). For the present study, where 
we focused on the 20 best-supported imprints for peptide 
synthesis, this led us to test more gag-ARF and pol-ARF 
than nef-ARF imprints for functional responses (Table II). 
Again, compared with analyses in the regular coding frame, 
this selection is unlikely to have reduced or overestimated the 
breadth of detectable responses, as the imprints reported in 
the first frame were located with comparable frequency in 
previously defined epitopes across the three proteins tested 
(unpublished  data). Also,  compared  with  response  rates  to 
regular coding frame–based screenings (i.e., traditional OLP-
based tests), the observed frequency of responses to ARF 
Figure 3.  Commonly occurring HIV variants can escape recogni-
tion. (A and B) Viral variants of the A*03-RR9 epitope occurring with 
>2% frequency in the British Columbia cohort were identified. Frequency 
of the analyzed variants in A*03-negative (black bars) and -positive (white 
bars) individuals are displayed (A). Recognition of the consensus sequence 
peptide and the three variants was assessed in A*03-RR9 responders. All 
five A*03-positive individuals tested recognized the consensus sequence 
(black bars) but not the variants with the S→P change at amino acid 
position 6 (RTSKAPLER) or the A→S change at position 5 (RTSKTSLER) of 
the epitope, suggesting that these variants are escape forms (gray bars). 
In contrast, two of the A*03-positive and one A*74-positive individuals 
recognized the S→A variant (RTSKAALER; white bar) as well (B).70 Immune selection pressure to frameshift epitopes | Berger et al.
estimate its total contribution to the global immune response 
to HIV from such analyses. Aside from simple statistical con-
siderations, such as insufficient power because of low allele 
frequency, fixation or near-to-fixation of escape variants in 
the population, and differential kinetics of reverting muta-
tions, the current analysis is likely to underestimate the true 
breadth of responses because of several additional reasons.   
A basic issue is that frameshifts or single nucleotide insertion 
in the viral genome may occur repetitively, and a final epitope 
sequence could contain sequences of more than one reading 
frame. Although some positions in the genome may be more 
or less frequently affected by frameshifts, it is thus possible 
that epitopes exist that are encoded by an essentially unpre-
dictably  vast  array  of  random  mosaic  epitope  sequences 
composed of more than one reading frame. The identifica-
tion of such potential epitopes based on HLA imprints is   
difficult, as all combinations of possible frameshifts in the   
power in our cohort for this allele or because of inconsistent 
or diverse escape patterns from this response.
A frequent limitation in HLA imprint studies is that effec-
tive CTL escape by the observed mutation is assumed rather 
than experimentally demonstrated. In this study, we assessed 
variant recognition, both on a peptide basis as well as by ex-
pressing variant viral sequences. As the data demonstrate, the 
common escape variant in position 6 of the RR9 epitope   
abrogated CTL recognition and control of viral replication.   
Effective CTL escape by such a mutation that is enriched   
in  individuals  expressing  the  restricting  HLA-A*03  allele 
lends further strong support to the in vivo relevance of this 
mutation and the effectiveness of the CTL immune pressure 
against the RR9 epitope.
HLA footprint analyses can only provide a partial picture 
of the host immune response to HIV, and it is difficult to 
judge the in vivo relevance of ARF-derived responses or to 
Figure 4.  A*03-RR9–specific CTLs inhibit viral replication. (A–E) Different virus variants were designed on an NL4-3 backbone (A) using site-
  directed mutagenesis and were tested in viral inhibition assays. CD4+ T cells were infected and co-cultured with an RR9-specific CD8+ clone from the same 
subject at various E/T ratios over 7 d. Viral inhibition was determined by p24 measurement in supernatants at days 3, 5, and 7. The consensus (B) but not 
the S→P variant (C) was strongly inhibited. Similarly, an R→G mutation at position 9, potentially disrupting MHC class I binding to A*03, was not inhib-
ited (D). The inhibition of viral replication of the consensus variant was dependent on the E/T ratio (E). One representative out of three independent  
experiments is shown. Inhibition assays were set up in triplicates.JEM VOL. 207, January 18, 2010 
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selection pressure against an epitope in the original HIV pro-
tein. Although this may usually be the case, it is a conserva-
tive  assumption  and  may  have  underestimated  the  true 
frequency of ARF-based CTL targets. On the other hand, it 
cannot be excluded that specific codon usage and preferred 
RNA structure for amino acids in the first frame may have 
driven some changes in the ARF while being synonymous in 
the regular coding frame.
The in vivo relevance of ARF-encoded epitopes will also 
depend on the likelihood of and the mechanisms involved in 
their production in virally infected cells. Data from a recent 
study suggest the possibility of ribosomal slippage being a po-
tential important mechanism given the RNA structure of 
HIV (Watts et al., 2009). However, to date, it still remains un-
clear to what level ARF-derived epitopes in HIV/SIV are a 
degradation product of functional proteins or RNA sequences 
encoded  by  the  frameshift  or  antisense  sequence  (Miller, 
1988; Landry et al., 2007), or are rather simply defective ribo-
somal products that result from accidental frameshift and 
are rapidly degraded (Yewdell and Nicchitta, 2006). The data 
shown in this study do not resolve this point but indicate 
that the use of alternative start codons could likely help the 
production of ARF epitopes, as the replacement of leucine 
vicinity of the imprint would need to be synthesized as test 
peptides. Despite this potential complexity, however, our 
data also indicate that HIV-infected cells seem to produce 
and  present  ARF-encoded  peptides  consistently  enough 
across individuals to result in population-based immune 
pressure reflected as population-wide HLA footprints. Fur-
ther documentation of how consistently HIV-infected cells 
may present ARF-encoded peptide sequences may also come 
from epitope elution studies using HIV-infected cells that 
may help to identify epitopes with partial sequence matches 
in different reading frames (Hickman et al., 2003).
Apart from statistical power to identify specific HLA al-
lele–associated imprints, ex vivo immune analyses will only 
reveal responses if they are present in an appreciable number 
of subjects. Although some of the most immunodominant 
known HIV epitopes are targeted by >50% of individuals ex-
pressing the respective restricting HLA allele, many responses 
are found less frequently and are only detected if the test co-
horts are massively expanded so that even infrequent alleles 
are represented several times (Bihl et al., 2006). In addition, 
HLA imprints in ARF that caused a nonsynonymous change 
in the first, coding frame were excluded in the present study, 
assuming that the observed change was driven by immune 
Figure 5.  Alternative start codon usage might be a mechanism for frameshift epitope expression of A*03-RR9. (A–D) To address if an up-
stream leucine could figure as a alternative start codon and therefore regulate expression of A*03-RR9, viral variants carrying a regular start codon (AUG, 
methionine) or lacking a potential start codon (valine instead of leucine) at this position were created (A). The inhibition of the variants by an RR9-specific 
CD8+ clone was assessed and compared with the consensus variant with the leucine. The L→V variant (C) was no longer inhibited, whereas the L→M 
variant (B) was more strongly inhibited than the L variant (3 vs. 1 log at an E/T ratio of 1:10 at day 7), pointing at a potential mechanism for the ex-
pression of A*03-RR9 (D). One representative out of three independent experiments is shown. Inhibition assays were set up in triplicates.72 Immune selection pressure to frameshift epitopes | Berger et al.
from further analysis because of a low probability that these epitopes were 
in fact expressed all the way in the same frame and would hence not be 
discovered by a peptide screen.
Assessment of T cell responses to frameshift-derived epitopes. To 
test for immune responses to ARF epitopes, 85 untreated chronically HIV-
infected individuals were recruited from hospitals in the Boston area. 32 
HIV-negative individuals were included as controls. From all individuals, 
fresh PBMCs were isolated from whole blood using density gradient centrif-
ugation and used in direct ex vivo ELISPOT assays as previously described 
(Frahm et al., 2004). In brief, 100,000 fresh PBMCs were incubated with 
peptides in pools of four peptides at a final concentration of 28 µg/ml in 96-
well polyvinylidene difluoride plates (Millipore) precoated with the anti–
IFN- mAb 1-D1K (Mabtech) according to the manufacturer’s instructions. 
A positive (PHA) and at least four negative (no peptide) controls were in-
cluded  for  each  individual  tested.  ELISPOT  results  were  expressed  as 
SFCs/106 input cells. The threshold for a positive response was defined as at 
least 50 SFCs/106 input cells and responses exceeding three times the mean 
of negative wells. Peptides were synthesized as listed in Table II. Specific ep-
itopes with an HLA-binding motif for the observed imprint were predicted 
using epitope prediction algorithms (available at http://atom.research.mi-
crosoft.com/bio/epipred.aspx [Heckerman et al., 2007] and www.hiv.lanl 
.gov/content/immunology). In brief, for each HLA-associated polymor-
phism, a consensus sequence was constructed from sequences that contained 
the predicted nonadapted form of the association, and Epipred was used to 
predict the likeliest epitope (9–11mer) within a window extending ±13 
amino acids from the observed HLA-associated polymorphism or until the 
first consensus stop codon. In cases where the imprint was not included in 
the predicted epitope, OLPs of 17–18 amino acids in length were designed 
and included in the screening (Fig. 1 C).
Determination of the functional avidity and HLA restriction analyses.  
The optimal epitope length was determined using sequential peptide trunca-
tions in serial 10-fold dilutions ranging from 100 to 0.0001 µg/ml (Frahm et 
al., 2007). Freshly isolated or frozen, unexpanded PBMCs were used in 
standard IFN- ELISPOT assays. The functional avidity, defined as the an-
tigen dose needed to elicit a concentration indicating half-maximal response 
(SD50%), was determined. The shortest peptide with the lowest SD50% was 
considered the optimal epitope (Frahm et al., 2008). HLA restriction was 
determined  using  standard  ELISPOT  assays  and  epitope-specific  TCLs. 
TCLs were used for restriction analysis after 10–14 d of peptide-specific in 
vitro expansion. EBV-transformed, partly HLA-matched B cell lines (BCLs) 
were used as APCs for restriction analysis, as previously described (Goulder 
et al., 2001). BCLs were incubated for 1 h with the optimal peptides at   
20 µg/ml, followed by extensive washing. BCLs without peptide were used 
as negative controls. Peptide-specific TCLs (E/T ratio of 1:1) and 2 µg/ml 
of  anti-CD28  and  -CD49d  co-stimulatory  antibodies  (BD)  were  added   
and incubated for 6 h at 37°C. For the last 5 h of incubation, 10 µg/ml 
Brefeldin A was added. Cells were fixed and permeabilized using Cytofix/
Cytoperm  (BD)  according  to  the  manufacturer’s  instructions,  and  the   
percentage  of  responding  cells  was  determined  using  anti-CD3–PerCP, 
anti-CD4–PE, anti-CD8–allophycocyanin, and anti–IFN-–FITC antibod-
ies (all from BD).
Viral variants expressing escape mutations and artificial start co-
dons in ARFs. Viruses harboring single or multiple point mutations in 
ARFs within and/or surrounding the A*03-RR9 epitope were created on 
an  NL4-3  backbone  using  site-directed  mutagenesis  (QuikChange  XL; 
Agilent Technologies) according to the manufacturer’s instructions. The 
viral variants generated and used in in vitro inhibition assays are summarized 
in Fig. 4 A and Fig. 5 A. Importantly, mutagenesis primers were designed 
to only cause synonymous changes in the primary ORF, meaning that the 
engineered point mutations did not disrupt the regular reading frame. NL4-
3 contains the sequence of the escape variant (RTSKAPLER). Therefore, 
we first created a virus variant that carries the clade B consensus sequence. 
Based on this P→S variant, the other viruses were created. The following primer 
with valine showed an abrogated suppression of viral replica-
tion and, presumably, RR9 presentation. Although the sub-
stitution  of  leucine  to  methionine  caused  significantly 
improved suppression of viral replication, the lower level ex-
pression of the leucine is probably sufficient to sensitize in-
fected cells for CTL recognition. This is in line with data by 
Sykulev et al. (1996) showing that a single peptide–MHC 
complex on a target cell might be sufficient to elicit a cyto-
lytic T cell response. Also, as the relative magnitude of re-
sponses and the relative abundance of presented epitopes do 
not necessarily correlate with in vivo protection (Gallimore 
et al., 1998), the expression level of the RR9 epitope and the 
magnitude of the response are likely not the only factors that 
determine its in vivo relevance. Regardless of this open ques-
tion, the present study is the first demonstration of popula-
tion-wide  viral  adaptation  to  immune  selection  pressure 
exerted by CTL responses targeting HLA class I–restricted 
epitopes encoded by HIV frameshifted sequences. These re-
sponses lead to effective CTL escape variants in vivo and 
were able to inhibit viral replication in vitro. Thus, they 
show all the characteristics that are commonly seen as impor-
tant attributes of an effective HIV-specific CTL immunity 
and may be considered for inclusion in HIV vaccine design.
MATERIALS AND METHODS
Ethical approval. The study was approved by the respective local ethics 
boards (Partners Institutional Review Board and Providence Health Care/
University of British Columbia Research Ethics Board).
Virus sequencing and HLA typing. Plasma RNA from 765 treatment-
naive, chronic, predominantly HIV clade B–infected (97.5%) subjects en-
rolled in the British Columbia HOMER Study was isolated and sequenced as 
previously described (Hogg et al., 2001). In brief, HIV RNA was extracted 
from a pretherapy plasma sample and HIV gag, protease, RT (codons 1–400), 
integrase, and nef were amplified using nested RT-PCR and bulk sequenced 
on an automated DNA sequencer (ABI 3700; Applied Biosystems). For all 
genes, data on at least 500 individuals were available (gag, n = 567; protease/
RT, n = 532; integrase, n = 582; and nef, n = 686). HLA class I typing was 
performed by sequence-based typing as previously described (Brumme et al., 
2007, 2008). Accession numbers of the sequences are listed in the respective 
publications (Brumme et al., 2007, 2008).
Identification of HLA-associated amino acid variation in HIV   
genomes. Gag, Pol, and Nef sequences were aligned to HXB2 and trans-
lated into the frameshifted reading frames +1 and +2. HLA-associated 
polymorphisms in the frameshifted sequences were identified using previ-
ously published, phylogenetically informed methods, which additionally 
correct for HLA linkage disequilibrium as well as HIV codon covariation 
(Carlson et al., 2008). Statistical significance is reported using q-values, 
which estimate the false discovery rate for each comparison (Storey and 
Tibshirani, 2003). We used a threshold of q ≤ 0.2, meaning that we expect 
a false-positive proportion of 20% among identified associations. To avoid 
identifying false-positive HLA associations in ARFs that could reflect im-
mune pressure on the regular ORF, all HLA associations in the +1 and +2 
ORFs were excluded when they were (a) associated with a nonsynony-
mous change at the same position in the first frame, (b) had an imprint for 
any other allele within ±2 amino acids in the original reading frame, or (c) 
had a known optimal epitope in the original reading frame that was re-
stricted by the same HLA allele for which the imprint was observed for the 
ARF. In addition, all regions with imprints in the +1 and +2 ORFs that 
had a length of <10 amino acids between two stop codons were excluded JEM VOL. 207, January 18, 2010 
Article
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